home / stock / mpsyf / mpsyf message board
Subject | By | Source | When |
---|---|---|---|
Emylers: MPSYF Financials 07/16/2014 03:24:38 MorphoSys AG Period Ending Total Revenue Cost of Reven | Emylers | investorshangout | 07/16/2014 8:24:35 AM |
Stock Tracker: Latest Morphosys Ag (MPSYF) Headlines Novartis Strengthens in Oncology With Multiple | Stock_Tracker | investorshangout | 03/10/2014 8:40:12 PM |
chartguy89: MPSYF 97.21 Stock Charts $MPSYF 1 Month Chart | chartguy89 | investorshangout | 03/08/2014 9:38:56 PM |
chartguy89: MPSYF Stock Charts Last: -0.70 Friday, February 28, 2014 at 2:05:11 AM $MPSYF 1 | chartguy89 | investorshangout | 02/28/2014 7:05:23 AM |
News, Short Squeeze, Breakout and More Instantly...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG. Novartis BidCo Germany ...
Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 24, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new efficacy and safety data from the Phase 3 MANIFEST-2 trial of pel...
Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billion Shareholders benefit from attractive premium of 94% and 142% on the volume-weighted average price during the last month and three months before January 25, 2024, respectively Acce...